This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lisy, O. Articles by Burnett, J. C. Search for Related Content PubMed PubMed Citation Articles by Lisy, O. Articles by Burnett, J. C., Jr Pubmed/NCBI databases Protein Compound via MeSH Substance via MeSH Medline Plus Health Information Heart Failure Related Collections Cardio-renal physiology/pathophysiology Cardiovascular Pharmacology Animal models of human disease

(Hypertension. 2001;37:1089.)
© 2001 American Heart Association, Inc.

Scientific Contribution

Therapeutic Actions of a New Synthetic Vasoactive and Natriuretic Peptide, Dendroaspis Natriuretic Peptide, in Experimental Severe Congestive Heart Failure

Presented in part at the 72nd Scientific Sessions of the American Heart Association, Atlanta, Ga, November 7-10, 1999, and published in abstract form (Circulation. 1999;100[suppl 1]:I–3354A.

Ondrej Lisy; John G. Lainchbury; Hanna Leskinen; John C. Burnett, Jr

From the Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Departments of Physiology and Internal Medicine, Mayo Clinic and Foundation, Rochester, Minn.

Correspondence to Ondrej Lisy, MD, Cardiorenal Research Laboratory, Mayo Clinic and Foundation, 200 First St SW, Rochester MN 55905. E-mail lisy.ondrej{at}mayo.edu

Abstract—Dendroaspis natriuretic peptide (DNP), a recently discovered peptide, shares structural similarity to the other known natriuretic peptides, ANP, BNP, and CNP. Studies have reported that DNP is present in human and canine plasma and atrial myocardium and increased in plasma of humans with congestive heart failure (CHF). In addition, synthetic DNP is markedly natriuretic and diuretic and is a potent activator of cGMP in normal animals. To date, the ability of synthetic DNP to improve cardiorenal function in experimental CHF is unknown. Synthetic DNP was administered intravenously at 10 and 50 ng · kg^-1 · min^-1 in dogs (n=7) with severe CHF induced by rapid ventricular pacing for 10 days at 245 bpm. In addition, we determined endogenous DNP in normal (n=4) and failing (n=4) canine atrial and ventricular myocardium. We report that administration of synthetic DNP in experimental severe CHF has beneficial cardiovascular, renal, and humoral properties. First, DNP in CHF decreased cardiac filling pressures, specifically right atrial pressure and pulmonary capillary wedge pressure. Second, DNP increased glomerular filtration rate in association with natriuresis and diuresis despite a reduction in mean arterial pressure. Third, DNP increased plasma and urinary cGMP and suppressed plasma renin activity. Fourth and finally, we report that DNP immunoreactivity is present in canine atrial and ventricular myocardium and increased in CHF. These studies report the acute intravenous actions of synthetic DNP in experimental severe CHF and suggest that on the basis of its beneficial properties, DNP may have potential as a new intravenous agent for the treatment of decompensated CHF.

Key Words: heart failure • natriuretic peptides • cyclic guanosine monophosphate • renin • endopeptidase

This article has been cited by other articles:

				P. M. McKie, A. Cataliotti, B. K. Huntley, F. L. Martin, T. M. Olson, and J. C. Burnett Jr A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure-lowering, renal-enhancing, and aldosterone-suppressing actions. J. Am. Coll. Cardiol., September 8, 2009; 54(11): 1024 - 1032. [Abstract] [Full Text] [PDF]

				G. Boerrigter, L. C. Costello-Boerrigter, G. J. Harty, B. K. Huntley, A. Cataliotti, H. Lapp, and J. C. Burnett Jr. B-type natriuretic peptide 8-32, which is produced from mature BNP 1-32 by the metalloprotease meprin A, has reduced bioactivity Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2009; 296(6): R1744 - R1750. [Abstract] [Full Text] [PDF]

				D. M. Dickey, J. C. Burnett Jr., and L. R. Potter Novel Bifunctional Natriuretic Peptides as Potential Therapeutics J. Biol. Chem., December 12, 2008; 283(50): 35003 - 35009. [Abstract] [Full Text] [PDF]

				O. Lisy, B. K. Huntley, D. J. McCormick, P. A. Kurlansky, and J. C. Burnett Jr Design, Synthesis, and Actions of a Novel Chimeric Natriuretic Peptide: CD-NP. J. Am. Coll. Cardiol., July 1, 2008; 52(1): 60 - 68. [Abstract] [Full Text] [PDF]

				L. C. Costello-Boerrigter, G. Boerrigter, G. J. Harty, A. Cataliotti, M. M. Redfield, and J. C. Burnett Jr Mineralocorticoid Escape by the Kidney But Not the Heart in Experimental Asymptomatic Left Ventricular Dysfunction Hypertension, September 1, 2007; 50(3): 481 - 488. [Abstract] [Full Text] [PDF]

				G. Boerrigter, L. C. Costello-Boerrigter, A. Cataliotti, H. Lapp, J.-P. Stasch, and J. C. Burnett Jr Targeting Heme-Oxidized Soluble Guanylate Cyclase in Experimental Heart Failure Hypertension, May 1, 2007; 49(5): 1128 - 1133. [Abstract] [Full Text] [PDF]

				G. Boerrigter, L. C. Costello-Boerrigter, G. J. Harty, H. Lapp, and J. C. Burnett Jr. Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2007; 292(2): R897 - R901. [Abstract] [Full Text] [PDF]

				C. E. Taplin, C. T. Cowell, M. Silink, and G. R. Ambler Fludrocortisone Therapy in Cerebral Salt Wasting Pediatrics, December 1, 2006; 118(6): e1904 - e1908. [Abstract] [Full Text] [PDF]

				S. Pan, R. Gulati, C. S. Mueske, T. A. Witt, A. Lerman, J. C. Burnett Jr., and R. D. Simari Gene transfer of a novel vasoactive natriuretic peptide stimulates cGMP and lowers blood pressure in mice Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2213 - H2218. [Abstract] [Full Text] [PDF]

				A. Cataliotti, G. Boerrigter, L. C. Costello-Boerrigter, J. A. Schirger, T. Tsuruda, D. M. Heublein, H. H. Chen, L. S. Malatino, and J. C. Burnett Jr Brain Natriuretic Peptide Enhances Renal Actions of Furosemide and Suppresses Furosemide-Induced Aldosterone Activation in Experimental Heart Failure Circulation, April 6, 2004; 109(13): 1680 - 1685. [Abstract] [Full Text] [PDF]

				G. Boerrigter, L. C. Costello-Boerrigter, A. Cataliotti, T. Tsuruda, G. J. Harty, H. Lapp, J.-P. Stasch, and J. C. Burnett Jr Cardiorenal and Humoral Properties of a Novel Direct Soluble Guanylate Cyclase Stimulator BAY 41-2272 in Experimental Congestive Heart Failure Circulation, February 11, 2003; 107(5): 686 - 689. [Abstract] [Full Text] [PDF]

				H. H. Chen, J. G. Lainchbury, and J. C. Burnett Jr Natriuretic peptide receptors and neutral endopeptidase in mediating the renal actions of a new therapeutic synthetic natriuretic peptide dendroaspis natriuretic peptide J. Am. Coll. Cardiol., September 18, 2002; 40(6): 1186 - 1191. [Abstract] [Full Text] [PDF]